9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions

9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions

MPJE Core Concept: The Poison Prevention Packaging Act (PPPA) of 1970 was enacted to safeguard young children from accidental ingestion of toxic household chemicals and prescription legend drugs. Candidates must know the enforcing agency (CPSC), technical packaging test effectiveness standards, strict restrictions on container reuse, rules governing patient and prescriber waivers, and the exact statutory list of drug exemptions.

---

1. Enforcing Agency & Legal Scope

• Enforcing Regulatory Authority: The PPPA is enforced by the Consumer Product Safety Commission (CPSC). It is NOT enforced by the FDA or DEA. (MPJE trick questions frequently test this administrative distinction).
• Scope of Coverage: Applies to all oral human prescription drugs, liquid and solid dosage forms, as well as designated hazardous OTC household substances (such as aspirin, liquid methyl salicylate >5%, iron-containing supplements >250 mg elemental iron, diphenhydramine >66 mg, ibuprofen >1 g, naproxen >250 mg, and loperamide >0.045 mg).
• Exempted Dosage Forms: Non-oral dosage forms—such as topical creams/ointments, eye drops, ear drops, nasal sprays, and inhalers—are automatically exempt from PPPA child-resistant packaging requirements because they are not intended for oral administration.

---

2. Technical Child-Resistant Effectiveness Testing Standards

To be certified as child-resistant, a container design must undergo rigorous panel testing mandated by CPSC protocol regulations:

• Child Testing Panel Standard: A test panel of children under 5 years of age (42–54 months old) is given the packaging. At least 80% of children must be unable to open the container within 10 minutes of testing (or within 5 minutes prior to a visual demonstration).
• Adult Senior Panel Standard: A test panel of adults aged 50 to 70 years old is given the container. At least 90% of adults must be able to open and properly reclose the container within 5 minutes on their first attempt, and within 1 minute on subsequent attempts.

---

3. Container Reuse Restrictions on Prescription Refills

When refilling a prescription, pharmacists must comply with strict physical container reuse regulations to prevent mechanical wear and tear from degrading safety closure performance:

• All-Plastic Prescription Vials & Closures: A pharmacist CANNOT reuse plastic vials or plastic safety closures when dispensing a refill. Both the plastic body and the plastic cap must be discarded and replaced with a new vial and new cap upon every fill.
• Glass Containers: Glass prescription vials may be reused upon refill ONLY IF a brand-new plastic safety closure/cap is used. (The glass body does not wear down, but the plastic threading on the cap degrades).
• Unit-Dose & Blister Packaging: Package designs where the container and closure are integral (e.g., unit-dose blister cards, memory packs) cannot be reused.

---

4. Waiver and Opt-Out Regulations: Patient vs. Prescriber

The PPPA permits exemptions from child-resistant packaging upon request, but strict legal differences separate patient waivers from prescriber waivers:

---

5. Complete Statutory List of Exemptions from PPPA Packaging

Congress and the CPSC have established explicit statutory exemptions for specific legend drugs where immediate, uninhibited patient access is vital for emergency medical care, or where packaging design makes child-resistant closures impractical. Candidates must memorize this complete MPJE statutory list:

1. Sublingual Nitroglycerin (SL NTG): All dosage strengths of sublingual nitroglycerin tablets (critical for immediate treatment of acute angina attacks).
2. Isosorbide Dinitrate: Sublingual and chewable forms in dosage strengths of 10 mg or less.
3. Erythromycin Ethylsuccinate (EES):
   • Oral suspensions and granules for oral suspension in package sizes containing no more than 8 grams of erythromycin.
   • EES tablets in package sizes containing no more than 16 grams of erythromycin.
4. Anhydrous Cholestyramine: Powder formulations packaged in individual packets.
5. Potassium Supplements: Unit-dose forms (effervescent tablets, liquid unit-doses, and dry powder packets) containing no more than 50 mEq of potassium per dose.
6. Sodium Fluoride: Liquid and tablet preparations containing no more than 264 mg of sodium fluoride per package.
7. Betamethasone Tablets: Package sizes containing no more than 12.6 mg of betamethasone.
8. Mebendazole Tablets: Package sizes containing no more than 600 mg of mebendazole.
9. Methylprednisolone Tablets: Package sizes containing no more than 84 mg of methylprednisolone (e.g., standard 4-day or 6-day Medrol Dosepak).
10. Colestipol Powder: Packaged in individual packets containing no more than 5 grams of colestipol.
11. Pancrelipase Preparations: All tablet, capsule, or powder formulations of pancrelipase.
12. Oral Contraceptives & Conjugated Estrogens: Dispensed in manufacturer unit-of-use memory-aid dispenser packages (e.g., 28-day dial-packs).
13. Prednisone Tablets: Package sizes containing no more than 105 mg of prednisone.
14. Sacrosidase (Sucrase) Preparations: Formulations in 3.2% glycerol and water.
15. Hormone Replacement Therapy (HRT): Products relying solely on one or more progestogen or estrogen substances.

Institutional Exception (Inpatient Hospital & Long-Term Care)

Drugs dispensed to institutionalized inpatients (e.g., hospital patients, nursing home residents) are exempt from PPPA child-resistant packaging requirements, provided that the medications are maintained in institutional stock and administered exclusively by licensed healthcare personnel (nurses, physicians).